The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses (NCT06128915) | Clinical Trial Compass
RecruitingPhase 4
The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses
United States60 participantsStarted 2024-01-08
Plain-language summary
This study focuses on the role of neutrophils in shaping the adaptive immune response to the anti-pneumococcal vaccine Prevnar-13 in young and elderly adults.
Who can participate
Age range21 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Both sexes
* Have not been vaccinated with any licensed or experimental pneumococcal vaccine
* Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old
* Free of acute infections within the last 2 weeks
* Did not take any anti-inflammatory medicine in the last week
* Did not ingest alcohol in the last 24 hours
* Ability and willingness to provide consent
Exclusion Criteria:
* Previous vaccination with any licensed or experimental pneumococcal vaccine
* Known hypersensitivity to vaccination and vaccine components
* Immune deficiency
* Use of immune-modulating or suppressive drugs
* Malignancies within the last 2 years
* Known hematological, rheumatic and inflammatory diseases
* Known chronic infections
* Poorly controlled chronic cardiovascular and metabolic conditions
* Pregnancy
* Dementia
What they're measuring
1
Pneumococcal Opsonophagocytic Killing Activity (OPH) by neutrophils from young versus old donors at 1 week and 1 month after vaccination